Neuphoria Therapeutics Inc. $NEUP

What the company doesAI summary of filing

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing small-molecule modulators of ion channels for neuropsychiatric and neurological disorders. The company's lead product candidate, BNC210, is an oral negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor that failed to meet its primary endpoint in a Phase 3 trial for social anxiety disorder in October 2025, leading to discontinuation of that program; the PTSD program remains clinic-ready but is paused pending completion of a proposed merger with Scancell Holdings plc. The company is pre-revenue and has dramatically scaled back operations, retaining only one full-time employee and primarily maintaining its intellectual property while relying on partnered programs including Merck's alpha7 receptor positive allosteric modulator program, a Pfizer-licensed KAT6 program, and a Carina Biotech CAR-T program, from which it may receive milestone payments and royalties. [10-K 2026-09-18]

Segments: BNC210 (alpha7 NAM for PTSD and SAD), Merck alpha7 PAM program (MK-1167, MK-4334), CTx CRC/Pfizer KAT6 program, Carina CNA3103 (CAR-T)